NCT01407263Active, not recruitingPhase 3
Trial of Modifications to Radical Prostatectomy
A Randomized Trial of Modifications to Radical Prostatectomy
Source: ClinicalTrials.gov · Last updated 17 Aug 2026
Brief summary (registry, in English)
This trial will evaluate whether the following aspect of surgical technique influence outcome: Lymph node dissection. In some patients, scans taken before surgery show that a lymph node has cancer. Surgeons make sure to remove those affect lymph nodes and all other lymph nodes in the area. However, it is not known whether removing lymph nodes helps prostate cancer patients whose scans do not show positive nodes. In this study, patients with clear scans will either receive a lymph node dissection or not."
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 3204 (actual)
- First submitted
- 29 Jul 2011
- Start date
- 1 Jul 2011
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Prostate cancer
- NCT number
- NCT01407263
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 3204
- From 1 Jul 2011 to the primary completion date, 31 Jul 2027
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any prior pelvic radiation therapy used to treat prostate cancer
- Hemostatic agent vs. no hemostatic agent
Other
- Lymphadenectomy vs no lymphadenectomy
- Presence of positive/suspicious pelvic nodes on MRI, CT or PSMA scan (positive/suspicious defined as a pelvic node \>15mm in short axis on CT or MRI, a PSMA avid node, or a node with abnormal morphology such as roundness or irregularity or loss of fatty hilum)
- No additional exclusion criteria
Who the study is looking for
- Patients do not have to be eligible for both modifications to be included in the study.
- Lymphadenectomy vs no lymphadenectomy:
- Patients 21 years or older scheduled for radical prostatectomy for treatment of prostate cancer with one of the consenting surgeons at MSKCC
- Hemostatic agent vs. no hemostatic agent
- Patients 21 years or older scheduled for minimally invasive radical prostatectomy for the treatment of prostate cancer with one of the consenting surgeons at MSKC
Age in the registry: 21 years to - · Sex: Male · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center at Basking Ridge Coordinator of this site? Confirm its status | Basking Ridge | United States | Unknown status |
| Memorial Sloan Kettering Westchester Coordinator of this site? Confirm its status | Harrison | United States | Unknown status |
| Memorial Sloan Kettering Bergen (Consent Only) Coordinator of this site? Confirm its status | Montvale | United States | Unknown status |
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| Memorial Sloan Kettering Cancer Center @ Nassau (Consent only) Coordinator of this site? Confirm its status | Uniondale | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.